Suppr超能文献

控制衰减参数评估肥胖多囊卵巢综合征患者的肝脂肪变性。

Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome.

机构信息

Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, China.

Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China.

出版信息

Front Endocrinol (Lausanne). 2023 Aug 31;14:1241734. doi: 10.3389/fendo.2023.1241734. eCollection 2023.

Abstract

OBJECTIVES

This study was performed to investigate the changes and influencing factors of liver controlled attenuation parameter (CAP) in obese patients with polycystic ovary syndrome (PCOS), and to determine the prevalence and risk factors of nonalcoholic fatty liver disease (NAFLD) in PCOS patients with obesity.

METHODS

Forty-one PCOS patients with obesity and twenty age- and body mass index (BMI)-matched control women without PCOS were enrolled in this study. General data, body composition, biochemical parameters, sex hormones, and liver CAP in the two groups were collected and compared. Liver CAP was measured using transient elastography.

RESULTS

NAFLD was more common in the Obese PCOS group than in the control group (75.61% vs. 45.00%, =0.018). Compared to the control group, the obese PCOS group showed apparent increases in alanine transaminase (ALT), aspartate transaminase (AST), CAP, triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), totle testosterone (TT), free androgen index (FAI), fasting insulin (FIns), and homeostasis model assessment-insulin resistance (HOMA-IR), along with lower high-density lipoprotein cholesterol (HDL-C) and sex hormone binding globulin (SHBG) levels. In addition, as shown by Spearman analysis, liver CAP in PCOS patients with obesity had a positive correlation with ALT, AST, TG, TT, FAI, FIns, and HOMA-IR, and a negative correlation with SHBG. Logistic regression analysis showed that TG, TT, FIns, and HOMA-IR were risk factors for NAFLD, while TT was an independent risk factor for NAFLD in PCOS patients with obesity.

CONCLUSION

PCOS patients with obesity had a significantly higher prevalence of NAFLD. Furthermore, in PCOS patients with obesity, liver CAP was associated with disorders of lipid metabolism, insulin resistance, and hyperandrogenemia, with elevated testosterone levels being an independent risk factor for NAFLD in PCOS patients with obesity.

摘要

目的

本研究旨在探讨肥胖多囊卵巢综合征(PCOS)患者肝控制衰减参数(CAP)的变化及其影响因素,并确定肥胖 PCOS 患者中非酒精性脂肪性肝病(NAFLD)的患病率和危险因素。

方法

本研究纳入了 41 例肥胖 PCOS 患者和 20 例年龄和体重指数(BMI)匹配的非 PCOS 对照组女性。收集并比较两组患者的一般资料、人体成分、生化指标、性激素和肝脏 CAP。采用瞬时弹性成像技术测量肝脏 CAP。

结果

肥胖 PCOS 组的 NAFLD 患病率高于对照组(75.61% vs. 45.00%,=0.018)。与对照组相比,肥胖 PCOS 组的丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、CAP、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、总睾酮(TT)、游离雄激素指数(FAI)、空腹胰岛素(FIns)和稳态模型评估-胰岛素抵抗指数(HOMA-IR)明显升高,而高密度脂蛋白胆固醇(HDL-C)和性激素结合球蛋白(SHBG)水平则明显降低。Spearman 分析结果显示,肥胖 PCOS 患者的肝脏 CAP 与 ALT、AST、TG、TT、FAI、FIns 和 HOMA-IR 呈正相关,与 SHBG 呈负相关。Logistic 回归分析显示,TG、TT、FIns 和 HOMA-IR 是 NAFLD 的危险因素,而 TT 是肥胖 PCOS 患者中 NAFLD 的独立危险因素。

结论

肥胖 PCOS 患者的 NAFLD 患病率明显更高。此外,在肥胖 PCOS 患者中,肝脏 CAP 与脂代谢紊乱、胰岛素抵抗和高雄激素血症有关,升高的睾酮水平是肥胖 PCOS 患者中 NAFLD 的独立危险因素。

相似文献

1
Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome.
Front Endocrinol (Lausanne). 2023 Aug 31;14:1241734. doi: 10.3389/fendo.2023.1241734. eCollection 2023.
6
Metabolic disparities between obese and non-obese patients with polycystic ovary syndrome: implications for endometrial receptivity indicators.
Gynecol Endocrinol. 2024 Dec;40(1):2312895. doi: 10.1080/09513590.2024.2312895. Epub 2024 Mar 6.
7
Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome.
World J Gastroenterol. 2020 Nov 28;26(44):7046-7060. doi: 10.3748/wjg.v26.i44.7046.
8
Insulin resistance and hyperandrogenemia independently predict nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
Diabetes Metab Syndr. 2019 Mar-Apr;13(2):1065-1069. doi: 10.1016/j.dsx.2018.12.020. Epub 2019 Jan 8.
9
Analyses of risk factors for polycystic ovary syndrome complicated with non-alcoholic fatty liver disease.
Exp Ther Med. 2018 May;15(5):4259-4264. doi: 10.3892/etm.2018.5932. Epub 2018 Mar 6.
10
Association of MEP1A gene variants with insulin metabolism in central European women with polycystic ovary syndrome.
Gene. 2014 Mar 10;537(2):245-52. doi: 10.1016/j.gene.2013.12.055. Epub 2014 Jan 2.

引用本文的文献

1
The signaling pathways in obesity-related complications.
J Cell Commun Signal. 2024 Jun 7;18(2):e12039. doi: 10.1002/ccs3.12039. eCollection 2024 Jun.

本文引用的文献

2
Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis.
Gut Microbes. 2023 Jan-Dec;15(1):2223339. doi: 10.1080/19490976.2023.2223339.
3
Polycystic Ovary Syndrome as Metabolic Disease: New Insights on Insulin Resistance.
touchREV Endocrinol. 2023 May;19(1):71-77. doi: 10.17925/EE.2023.19.1.71. Epub 2023 May 17.
5
Insulin resistance, autophagy and apoptosis in patients with polycystic ovary syndrome: Association with PI3K signaling pathway.
Front Endocrinol (Lausanne). 2022 Dec 16;13:1091147. doi: 10.3389/fendo.2022.1091147. eCollection 2022.
9
[Expert Consensus on Obesity Prevention and Treatment in China].
Zhonghua Liu Xing Bing Xue Za Zhi. 2022 May 10;43(5):609-626. doi: 10.3760/cma.j.cn112338-20220402-00253.
10
Current Perspectives on Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome.
Diabetes Metab Syndr Obes. 2022 Apr 24;15:1281-1291. doi: 10.2147/DMSO.S362424. eCollection 2022.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验